Literature DB >> 32661108

Effect of Afrezza on Glucose Dynamics During HCL Treatment.

Alfonso Galderisi1,2, Nathan Cohen3, Peter Calhoun3, Kristen Kraemer4, Marc Breton5, Stuart Weinzimer4, Eda Cengiz4,6.   

Abstract

OBJECTIVE: A major obstacle in optimizing the performance of closed-loop automated insulin delivery systems has been the delay in insulin absorption and action that results from the subcutaneous (SC) route of insulin delivery leading to exaggerated postmeal hyperglycemic excursions. We aimed to investigate the effect of Afrezza inhaled insulin with ultrafast-in and -out action profile on improving postprandial blood glucose control during hybrid closed-loop (HCL) treatment in young adults with type 1 diabetes. RESEARCH DESIGN AND METHODS: We conducted an inpatient, three-way, randomized crossover standardized meal study to assess the efficacy and safety of Afrezza at a low (AL) and a high (AH) dose as compared with a standard SC rapid-acting insulin (aspart) premeal bolus during Diabetes Assistant (DiAs) HCL treatment. Participants received two sequential meals on three study days, and premeal insulin bolus was determined based on home insulin-to-carbohydrate ratio for each meal (rounded up to the closest available Afrezza cartridge dose for AH and down for AL). The primary efficacy outcome was the peak postprandial plasma glucose (PPG) level calculated by pooling data for up to 4 h after the start of each meal. Secondary outcomes included hyperglycemic, hypoglycemic, and euglycemic venous glucose metrics.
RESULTS: The mean ± SD PPG for the rapid-acting insulin control arm and AH was similar (185 ± 50 mg/dL vs. 195 ± 46 mg/dL, respectively; P = 0.45), while it was higher for meals using AL (208 ± 54 mg/dL, P = 0.04). The AH achieved significantly lower early PPG level than the control arm (30 min; P < 0.001), and improvement in PPG waned at later time points (120 and 180 min; P = 0.02) coinciding with the end of Afrezza glucodynamic action.
CONCLUSIONS: Afrezza (AH) premeal bolus reduced the early glycemic excursion and improved PPG during HCL compared with aspart premeal bolus. The improvement in PPG was not sustained after the end of Afrezza glucodynamic action at 120 min.
© 2020 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32661108      PMCID: PMC7440894          DOI: 10.2337/dc20-0091

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  27 in total

1.  Clinical results of an automated artificial pancreas using technosphere inhaled insulin to mimic first-phase insulin secretion.

Authors:  Howard Zisser; Eyal Dassau; Justin J Lee; Rebecca A Harvey; Wendy Bevier; Francis J Doyle
Journal:  J Diabetes Sci Technol       Date:  2015-04-21

2.  DiAs web monitoring: a real-time remote monitoring system designed for artificial pancreas outpatient trials.

Authors:  Jérôme Place; Antoine Robert; Najib Ben Brahim; Patrick Keith-Hynes; Anne Farret; Marie-Josée Pelletier; Bruce Buckingham; Marc Breton; Boris Kovatchev; Eric Renard
Journal:  J Diabetes Sci Technol       Date:  2013-11-01

3.  Faster Compared With Standard Insulin Aspart During Day-and-Night Fully Closed-Loop Insulin Therapy in Type 1 Diabetes: A Double-Blind Randomized Crossover Trial.

Authors:  Klemen Dovc; Claudia Piona; Gül Yeşiltepe Mutlu; Natasa Bratina; Barbara Jenko Bizjan; Dusanka Lepej; Revital Nimri; Eran Atlas; Ido Muller; Olga Kordonouri; Torben Biester; Thomas Danne; Moshe Phillip; Tadej Battelino
Journal:  Diabetes Care       Date:  2019-10-01       Impact factor: 19.112

Review 4.  Postprandial glucose regulation and diabetic complications.

Authors:  Antonio Ceriello; Markolf Hanefeld; Lawrence Leiter; Louis Monnier; Alan Moses; David Owens; Naoko Tajima; Jaakko Tuomilehto
Journal:  Arch Intern Med       Date:  2004-10-25

5.  The influence of glucagon on postprandial hyperglycaemia in children 5 years after onset of type 1 diabetes.

Authors:  Siri Fredheim; Marie-Louise M Andersen; Sven Pörksen; Lotte B Nielsen; Christian Pipper; Lars Hansen; Jens J Holst; Jane Thomsen; Jesper Johannesen; Henrik B Mortensen; Jannet Svensson
Journal:  Diabetologia       Date:  2014-12-27       Impact factor: 10.122

Review 6.  The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences.

Authors:  P D Home
Journal:  Diabetes Obes Metab       Date:  2012-03-09       Impact factor: 6.577

7.  Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.

Authors:  Juris J Meier; Baptist Gallwitz; Stefan Salmen; Oliver Goetze; Jens J Holst; Wolfgang E Schmidt; Michael A Nauck
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

8.  Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide.

Authors:  Jennifer L Sherr; Neha S Patel; Camille I Michaud; Miladys M Palau-Collazo; Michelle A Van Name; William V Tamborlane; Eda Cengiz; Lori R Carria; Eileen M Tichy; Stuart A Weinzimer
Journal:  Diabetes Care       Date:  2016-05-05       Impact factor: 19.112

9.  Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device.

Authors:  Eda Cengiz; Stuart A Weinzimer; Jennifer L Sherr; Eileen Tichy; Melody Martin; Lori Carria; Amy Steffen; William V Tamborlane
Journal:  Pediatr Diabetes       Date:  2012-10-28       Impact factor: 4.866

Review 10.  Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled Insulin.

Authors:  Lutz Heinemann; Robert Baughman; Anders Boss; Marcus Hompesch
Journal:  J Diabetes Sci Technol       Date:  2016-07-09
View more
  2 in total

Review 1.  Recent advances in closed-loop insulin delivery.

Authors:  Julia Ware; Roman Hovorka
Journal:  Metabolism       Date:  2021-12-07       Impact factor: 8.694

2.  Adjunctive Therapies to Optimize Closed-loop Glucose Control.

Authors:  Shylaja Srinivasan; Laya Ekhlaspour; Eda Cengiz
Journal:  J Diabetes Sci Technol       Date:  2021-07-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.